Terms: = Leukemia AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
668 results:
1. Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in leukemia.
Pandey S; Singh R; Habib N; Tripathi RM; Kushwaha R; Mahdi AA
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1121-1134. PubMed ID: 38679971
[TBL] [Abstract] [Full Text] [Related]
2. [Effect of Shikonin on Autophagy and Apoptosis of Human Promyelocytic leukemia Cells].
Chen Y; Xie XM; Zhang XL; Zhang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):416-421. PubMed ID: 38660845
[TBL] [Abstract] [Full Text] [Related]
3. [Correlation of
Wang LY; Jiang PF; Li JZ; Chen YX; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):395-401. PubMed ID: 38660842
[TBL] [Abstract] [Full Text] [Related]
4. Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mtorC1 pathway-mediated apoptosis and autophagy.
Xu J; Zong S; Sheng T; Zheng J; Wu Q; Wang Q; Tang A; Song Y; Fei Y; Li Z
Int J Hematol; 2024 May; 119(5):541-551. PubMed ID: 38530586
[TBL] [Abstract] [Full Text] [Related]
5. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells.
Yadav AK; Wang S; Shin YM; Jang BC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
[TBL] [Abstract] [Full Text] [Related]
6. Renin-Angiotensin System Inhibitors Suppress the Growth of leukemia Cells.
Itoh M; Sasaki S; Tohda S
Anticancer Res; 2024 Mar; 44(3):1183-1192. PubMed ID: 38423665
[TBL] [Abstract] [Full Text] [Related]
7. Long non-coding RNA small nucleolar RNA host gene 29 drives chronic myeloid leukemia progression via microRNA-483-3p/Casitas B-lineage Lymphoma axis-mediated activation of the phosphoinositide 3-kinase/Akt pathway.
Feng X; Yang L; Liu X; Liu M; Liu L; Liu J; Luo J
Med Oncol; 2024 Jan; 41(2):60. PubMed ID: 38252204
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of PI3K-AKT-mtor pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells.
Şansaçar M; Sağır H; Gencer Akçok EB
Med Oncol; 2023 Dec; 41(1):31. PubMed ID: 38148433
[TBL] [Abstract] [Full Text] [Related]
9. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
[TBL] [Abstract] [Full Text] [Related]
10. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
Zagami P; Fernandez-Martinez A; Rashid NU; Hoadley KA; Spears PA; Curigliano G; Perou CM; Carey LA
JAMA Netw Open; 2023 Dec; 6(12):e2348814. PubMed ID: 38117494
[TBL] [Abstract] [Full Text] [Related]
11. Targeting S100A9 protein affects mtor-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid leukemia.
Fan R; Satilmis H; Vandewalle N; Verheye E; De Bruyne E; Menu E; De Beule N; De Becker A; Ates G; Massie A; Kerre T; Törngren M; Eriksson H; Vanderkerken K; Breckpot K; Maes K; De Veirman K
Blood Cancer J; 2023 Dec; 13(1):188. PubMed ID: 38110349
[TBL] [Abstract] [Full Text] [Related]
12. Ovatodiolide induces autophagy-mediated cell death through the p62-Keap1-Nrf2 signaling pathway in chronic myeloid leukemia cells.
Xia Q; Xie J; Zhang J; Zhang L; Zhou Y; Zhu B; Wu Y; Yang Z; Li J
Chem Biol Interact; 2024 Jan; 387():110819. PubMed ID: 38000454
[TBL] [Abstract] [Full Text] [Related]
13. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A; Aldoss I; Atherton PJ; Strand CA; Shah B; Webster J; Bhatnagar B; Flatten KS; Peterson KL; Schneider PA; Buhrow SA; Kong J; Reid JM; Adjei AA; Kaufmann SH
Cancer Med; 2023 Dec; 12(23):21229-21239. PubMed ID: 37960985
[TBL] [Abstract] [Full Text] [Related]
14. Combination therapy of acute myeloid leukemia by dual PI3K/mtor inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model.
Taghiloo S; Ajami A; Alizadeh-Navaei R; Asgarian-Omran H
Int Immunopharmacol; 2023 Dec; 125(Pt B):111211. PubMed ID: 37956488
[TBL] [Abstract] [Full Text] [Related]
15. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mtor signaling and suppression of mitochondrial biogenesis.
Tseng CY; Fu YH; Ou DL; Lu JW; Hou HA; Lin LI
Cancer Gene Ther; 2023 Dec; 30(12):1691-1701. PubMed ID: 37821641
[TBL] [Abstract] [Full Text] [Related]
16. m6A-Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic leukemia.
Wu Z; Zuo X; Zhang W; Li Y; Gui R; Leng J; Shen H; Pan B; Fan L; Li J; Jin H
Adv Sci (Weinh); 2023 Dec; 10(34):e2304895. PubMed ID: 37821382
[TBL] [Abstract] [Full Text] [Related]
17. Inhibition of the NOTCH and mtor pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract] [Full Text] [Related]
18. mtorC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
Malik N; Hay J; Almuhanna HNB; Dunn KM; Lees J; Cassels J; Li J; Nakagawa R; Sansom OJ; Michie AM
Leukemia; 2023 Dec; 37(12):2414-2425. PubMed ID: 37775560
[TBL] [Abstract] [Full Text] [Related]
19.
Giraud JS; Bièche I; Pasmant É; Tlemsani C
Expert Opin Investig Drugs; 2023; 32(10):941-957. PubMed ID: 37747491
[TBL] [Abstract] [Full Text] [Related]
20. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
[TBL] [Abstract] [Full Text] [Related]
[Next]
